Lantheus Holdings, Inc. $LNTH Shares Sold by Keybank National Association OH

Keybank National Association OH decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 47.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,800 shares of the medical equipment provider’s stock after selling 20,831 shares during the period. Keybank National Association OH’s holdings in Lantheus were worth $1,729,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Smartleaf Asset Management LLC lifted its holdings in Lantheus by 63.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 298 shares during the last quarter. Osterweis Capital Management Inc. bought a new position in shares of Lantheus during the second quarter valued at approximately $36,000. Los Angeles Capital Management LLC acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $39,000. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Lantheus by 71.4% in the 4th quarter. Farther Finance Advisors LLC now owns 660 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 275 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LNTH has been the subject of a number of recent research reports. Citigroup restated an “outperform” rating on shares of Lantheus in a research note on Friday, May 8th. Citizens Jmp restated a “market outperform” rating and set a $115.00 price target on shares of Lantheus in a research report on Monday, June 29th. The Goldman Sachs Group reiterated a “neutral” rating and issued a $94.00 price objective on shares of Lantheus in a research report on Thursday, May 7th. Truist Financial restated a “buy” rating and issued a $115.00 target price (up from $98.00) on shares of Lantheus in a research report on Monday, May 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $110.00 price target on shares of Lantheus in a report on Tuesday, March 17th. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $101.86.

Lantheus Price Performance

LNTH stock traded down $1.51 during trading on Tuesday, hitting $101.31. The company had a trading volume of 193,711 shares, compared to its average volume of 959,031. The firm has a market capitalization of $6.60 billion, a price-to-earnings ratio of 24.13 and a beta of -0.06. The business has a 50 day moving average of $98.94 and a 200 day moving average of $81.89. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $111.86. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.21. The firm had revenue of $377.33 million during the quarter, compared to analyst estimates of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue was up 1.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, research analysts predict that Lantheus Holdings, Inc. will post 4.49 earnings per share for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.